Thelansis

Diffuse Cutaneous Systemic Sclerosis (Dcssc) Market Outlook Thelansis’s “Diffuse Cutaneous Systemic Sclerosis (Dcssc) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Diffuse Cutaneous Systemic Sclerosis (Dcssc) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which e...

Diffuse Cutaneous Systemic Sclerosis (Dcssc) Market Outlook Thelansis’s “Diffuse Cutaneous Systemic Sclerosis (Dcssc) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Diffuse Cutaneous Systemic Sclerosis (Dcssc) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Diffuse Cutaneous Systemic Sclerosis (Dcssc) Overview Diffuse cutaneous systemic sclerosis (dcSSc) is a subtype of Systemic Sclerosis (SSc), a disease characterized by truncal and acral skin fibrosis with an early and significant incidence of diffuse involvement (interstitial lung disease, oliguric renal failure, diffuse gastrointestinal disease, and myocardial involvement)...

  Diffuse cutaneous systemic sclerosis (dcSSc) is a subtype of Systemic Sclerosis (SSc), a disease characterized by truncal and acral skin fibrosis with an early and significant incidence of diffuse involvement (interstitial lung disease, oliguric renal failure, diffuse gastrointestinal disease, and myocardial involvement). The disease typically occurs in middle-aged individuals, with Raynaud's phenomenon as an early sign. Common manifestations include skin hardening, telangiectasias, tendon friction rubs, and esophageal dysmotility. Arthralgias, acroosteolysis, muscular pain and weakness, and cramps may also occur. The disease can be life-threatening due to severe complications such as renal crisis, digestive involvement, lung fibrosis, and pulmonary arterial hypertension. Differential diagnosis includes several other autoimmune disorders. The prognosis for dcSSc is severe, with a 10-year survival rate of 60-80%. The prevalence is estimated at 1/25,000 adults. Women are p...